Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
19,711,628
-
Total 13F shares
-
12,370,024
-
Share change
-
+16,109
-
Total reported value
-
$18,058,661
-
Put/Call ratio
-
12%
-
Price per share
-
$1.46
-
Number of holders
-
53
-
Value change
-
-$595,250
-
Number of buys
-
22
-
Number of sells
-
23
Institutional Holders of Viracta Therapeutics, Inc. - Common Stock (VIRX) as of Q4 2022
As of 31 Dec 2022,
Viracta Therapeutics, Inc. - Common Stock (VIRX) was held by
53 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
12,370,024 shares.
The largest 10 holders included
BVF INC/IL, CITADEL ADVISORS LLC, Rubric Capital Management LP, VANGUARD GROUP INC, Laurion Capital Management LP, Samsara BioCapital, LLC, BlackRock Inc., MAI Capital Management, ADAGE CAPITAL PARTNERS GP, L.L.C., and Aisling Capital Management LP.
This page lists
53
institutional shareholders reporting positions in this security
for the Q4 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.